Your browser doesn't support javascript.
loading
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam, Martina; Beck, Susanne; Benes, Vladimir; Salwender, Hans; Bertsch, Uta; Scheid, Christoph; Hänel, Mathias; Weisel, Katja; Hielscher, Thomas; Raab, Marc S; Goldschmidt, Hartmut; Jauch, Anna; Maes, Ken; De Bruyne, Elke; Menu, Eline; De Veirman, Kim; Moreaux, Jérôme; Vanderkerken, Karin; Seckinger, Anja; Hose, Dirk.
Afiliação
  • Emde-Rajaratnam M; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • Beck S; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • Benes V; Universitätsklinikum Heidelberg, Molekularpathologisches Zentrum, Heidelberg, Germany.
  • Salwender H; Europäisches Laboratorium für Molekularbiologie, GeneCore, Heidelberg, Germany.
  • Bertsch U; Asklepios Tumorzentrum Hamburg, AK Altona and St. Georg, Hamburg, Germany.
  • Scheid C; Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany.
  • Hänel M; Department I of Internal Medicine, University of Cologne, Cologne, Germany.
  • Weisel K; Department of Internal Medicine III, Klinikum Chemnitz GmbH, Chemnitz, Germany.
  • Hielscher T; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Raab MS; Deutsches Krebsforschungszentrum, Abteilung für Biostatistik, Heidelberg, Germany.
  • Goldschmidt H; Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany.
  • Jauch A; Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany.
  • Maes K; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany.
  • De Bruyne E; Universität Heidelberg, Institut für Humangenetik, Heidelberg, Germany.
  • Menu E; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • De Veirman K; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • Moreaux J; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • Vanderkerken K; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • Seckinger A; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France.
  • Hose D; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
Front Immunol ; 14: 1286700, 2023.
Article em En | MEDLINE | ID: mdl-38035078
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica